Martin Haluzík, Head of Diabetes Centre at Institute for Clinical and Experimental Medicine, President of the Czech Obesity Society, shared a post on LinkedIn about a recent article by Aditya Mahadevan et al. published in The Journal of Clinical Endocrinology & Metabolism:
“GLP-1 Receptor Agonists in Patients with Cancer are Associated with Reduced All-Cause Mortality and Hospitalization
Very interesting paper just published in JCEM by Aditya M. and colleagues.
- GLP- 1 RA have been reported to decrease cancer incidence, but less is known about their potential in patients with active cancer. Preclinical studies have demonstrated that GLP-1 RA inhibit progression of solid tumor malignancies via downregulation of cellular proliferation pathways and improved glycemic control.
- Using TriNetX, a global database comprising over 120 million patients, we identified an overall cohort of 3747 patients with type 2 diabetes who received GLP-1 RA within 3 months of starting systemic therapy and identified 52,061 patients receiving metformin in the same timeframe as a control cohort.
- Patients receiving GLP-1 RA had significantly reduced mortality in both the overall monotherapy setting (HR: 0.875, 95% CI: (0.778-0.985), p=0.0268) and the new start setting (HR: 0.786 , 95% CI: (0.662-0.934), p= 0.0062) cohorts.
- Secondary analyses found lower rates of all-cause hospitalization, sepsis, major adverse cardiovascular events, pulmonary embolism, and pneumonia in patients on GLP-1 RA. Sub-analyses stratified by BMI and A1c did not meet statistical significance.
- Patients with diabetes and cancer who received GLP-1 RA experienced superior survival outcomes and reduced rates of hospitalization compared to patients receiving metformin.
- Additionally, patients already on metformin and newly started on GLP-1 RA demonstrated superior survival outcomes compared to patients newly started on insulin. Further prospective, well-controlled studies are needed to evaluate the benefits of GLP-1 RA in patients with diabetes and cancer.
Very interesting data.
GLP-1 treatment of T2DM cancer patients reduced mortality and hospitalizations even with those on metformin alone.
This is quite significant as metformin has been associated with reduction of some forms of cancer (e.g. breat cancer)
In additioon to reduced mortality, secondary analyses found lower rates of all-cause hospitalization, sepsis, MACE, pulmonary embolism, and pneumonia in patients on GLP-1 RA.
As always, we need randomized trials to confirm but this is very exciting data
Very well written an important paper! Congratiulations to the authors!”
Title: GLP- 1 Receptor Agonists in Patients with Cancer are Associated with Reduced All-Cause Mortality and Hospitalization
Authors: Aditya Mahadevan; Aidan Vosooghi; Jagmeet S. Arora, BS; Ruthvik Sunil Kumar; Gagandeep Singh, BS; Katy K. Tsai; Zoe Quandt
Read the Full Article on The Journal of Clinical Endocrinology & Metabolism
More posts about GLP-1 Receptor Agonists.
